Literature DB >> 10548562

Testing for and clinical significance of anticardiolipin antibodies.

S W Reddel1, S A Krilis.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10548562      PMCID： PMC95774          DOI： 10.1128/CDLI.6.6.775-782.1999

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


× No keyword cloud information.
  82 in total

1.  Heat treatment of serum and plasma induces false positive results in the antiphospholipid antibody ELISA.

Authors:  P Hasselaar; D A Triplett; A LaRue; R H Derksen; L Blokzijl; P G de Groot; D R Wagenknecht; J A McIntyre
Journal:  J Rheumatol       Date:  1990-02       Impact factor: 4.666

2.  Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients.

Authors:  D Alarcón-Segovia; M Delezé; C V Oria; J Sánchez-Guerrero; L Gómez-Pacheco; J Cabiedes; L Fernández; S Ponce de León
Journal:  Medicine (Baltimore)       Date:  1989-11       Impact factor: 1.889

3.  The anticardiolipin syndrome.

Authors:  G R Hughes
Journal:  Clin Exp Rheumatol       Date:  1985 Oct-Dec       Impact factor: 4.473

4.  Blocking coagulation inhibitors in children taking penicillin.

Authors:  D J Orris; J H Lewis; J A Spero; U Hasiba
Journal:  J Pediatr       Date:  1980-09       Impact factor: 4.406

5.  beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway.

Authors:  I Schousboe
Journal:  Blood       Date:  1985-11       Impact factor: 22.113

6.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).

Authors:  H P McNeil; R J Simpson; C N Chesterman; S A Krilis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

7.  Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.

Authors:  E N Harris; A E Gharavi; M L Boey; B M Patel; C G Mackworth-Young; S Loizou; G R Hughes
Journal:  Lancet       Date:  1983-11-26       Impact factor: 79.321

8.  Fall in antiphospholipid antibody at time of thromboocclusive episodes in systemic lupus erythematosus.

Authors:  C Drenkard; J Sánchez-Guerrero; D Alarcón-Segovia
Journal:  J Rheumatol       Date:  1989-05       Impact factor: 4.666

9.  Recurrent venous thrombosis with a "lupus" coagulation inhibitor in the absence of systemic lupus.

Authors:  A Manoharan; L Gibson; B Rush; B J Feery
Journal:  Aust N Z J Med       Date:  1977-08

10.  A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome.

Authors:  S P Bajaj; S I Rapaport; D S Fierer; K D Herbst; D B Schwartz
Journal:  Blood       Date:  1983-04       Impact factor: 22.113
View more
  4 in total

1.  Authors' reply.

Authors:  Vishal Gupta; Snehal Agrawal; G N Abhishek; Shipra Agarwal; Kanika Sahni
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 May-Jun       Impact factor: 2.545

2.  Detection of 'antiphospholipid' antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding beta(2)-glycoprotein I and prothrombin.

Authors:  Y Sheng; J G Hanly; S W Reddel; S Kouts; J Guerin; T Koike; K Ichikawa; A Sturgess; S A Krilis
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

3.  Anti-lysobisphosphatidic acid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus.

Authors:  C Alessandri; M Bombardieri; L Di Prospero; P Conigliaro; F Conti; G Labbadia; R Misasi; M Sorice; G Valesini
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

Review 4.  Stiff person syndrome with elevated titers of antibodies against cardiolipin and β2 glycoprotein 1: a case report and literature review.

Authors:  Li-Ya Tang; Sheng-Yuan Yu; Yong-Hua Huang
Journal:  J Musculoskelet Neuronal Interact       Date:  2018-09-01       Impact factor: 2.041
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.